Skip to main content
profile image
Selected Works of Daniel F. Kelly, MD
Article
Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors.
CNS Oncol
  • David E Piccioni
  • Achal Singh Achrol, Department of Neurosurgery and Neurosciences, John Wayne Cancer Institute and Pacific Neuroscience Institute, Santa Monica, CA, USA
  • Lesli A Kiedrowski
  • Kimberly C Banks
  • Najee Boucher, Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
  • Garni Barkhoudarian, John Wayne Cancer Institute Santa Monica, California.
  • Daniel F Kelly, Pacific Neuroscience Institute, Brain Tumor Center & Pituitary Disorders Program, John Wayne Cancer Institute at Providence Saint John's Health Center, 2200 Santa Monica Blvd., Santa Monica, CA, 90404, USA.
  • Tiffany Juarez, Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA.
  • Richard B Lanman
  • Victoria M Raymond
  • Minhdan Nguyen, Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
  • Judy D Truong, Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
  • Annie Heng, Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
  • Jaya Mini Gill, John Wayne Cancer Institute
  • Marlon G Saria, Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California
  • Sandeep C Pingle
  • Santosh Kesari, Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.
Download
Document Type
Article
Publication Date
6-1-2019
Disciplines
Abstract

Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. Methods: Data from 419 PBT patients tested clinically with a ctDNA NGS panel at a CLIA-certified laboratory were analyzed. Results: A total of 211 patients (50%) had ≥1 somatic alteration detected. Detection was highest in meningioma (59%) and gliobastoma (55%). Single nucleotide variants were detected in 61 genes, with amplifications detected in ERBB2, MET, EGFR and others. Conclusion: Contrary to previous studies with very low yields, we found half of PBT patients had detectable ctDNA with genomically targetable off-label or clinical trial options for almost 50%. For those PBT patients with detectable ctDNA, plasma cfDNA genomic analysis is a clinically viable option for identifying genomically driven therapy options.

Specialty
Nursing
Citation Information
David E Piccioni, Achal Singh Achrol, Lesli A Kiedrowski, Kimberly C Banks, et al.. "Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors." CNS Oncol (2019)
Available at: http://works.bepress.com/daniel-kelly/232/